innovation
Advanced HPV RNA-Seq Test developed by the Institut Pasteur : exclusive license signed with ABL Diagnostics
The Institut Pasteur, a Carnot institute since 2007, and ABL Diagnostics, a Euronext-listed leader in molecular diagnostics, recently signed a licensing agreement for the integration of the innovative HPV RNA sequencing technology into ABL Diagnostics solutions, which will produce and market the test.
HPV RNA-Seq is a cutting-edge diagnostic method that enhances the detection and typing of high-risk human papillomavirus (HPV) infections. This technology not only identifies the presence of HPV but also determines the specific viral strains and assesses the risk of progression to cervical cancer. HPV RNA-Seq demonstrated superior sensitivity compared to traditional DNA-based tests, detecting additional HPV-positive cases and multiple infections that were previously unrecognized.